Good Manufacturing Practices for Cosmetic Products Listening Session
Speakers' Biographies

Namandjé N. Bumpus, Ph.D., Chief Scientist, FDA. Dr. Namandjé N. Bumpus was named as the FDA's Chief Scientist on June 30, 2022. The Office of the Chief Scientist supports the research foundation, science, and innovation that underpins the FDA's regulatory mission. It does this through a broad framework that encompasses scientific collaborations, laboratory safety, the transfer of FDA inventions to the private sector, scientific integrity in FDA policy- and decision-making, the professional development of regulatory scientists, and its core research component—the FDA's National Center for Toxicological Research—which generates the vital data that the FDA requires for its regulatory decision-making and development of sound regulatory policy.

Before joining the FDA, Dr. Bumpus was the E.K. Marshall and Thomas H. Maren Professor and chair of the Department of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine. She served previously as associate dean for basic research in the Johns Hopkins University School of Medicine. Dr. Bumpus' research has focused on drug metabolism, pharmacogenetics, bioanalytical chemistry, and infectious disease pharmacology. Dr. Bumpus joined the faculty at Johns Hopkins in 2010 as an assistant professor. She earned a bachelor's degree in biology at Occidental College in 2003, a doctorate in pharmacology at the University of Michigan in 2007 and completed a postdoctoral fellowship in molecular and experimental medicine at The Scripps Research Institute in La Jolla, CA in 2010.

Dr. Bumpus currently serves as president-elect of the American Society for Pharmacology and Experimental Therapeutics. She previously served as chair of the NIH Xenobiotic and Nutrient Disposition and Action study section.

Her many honors include the Leon I. Goldberg Award from the American Society for Clinical Pharmacology and Therapeutics, the James Gillette Award from the International Society for the Study of Xenobiotics, the John J. Abel Award in Pharmacology from the American Society for Pharmacology and Experimental Therapeutics and the Presidential Early Career Award for Scientists and Engineers, which is the highest honor bestowed by the United States government on early career scientists and engineers. Dr. Bumpus is an elected fellow of the American Association for the Advancement of Science and an honorary member of the Society of Toxicology. She became a Member of the National Academy of Medicine, Class of 2022, one of the highest honors in the fields of health, science and medicine.

Linda M. Katz, M.D., M.P.H., F.A.C.P., F.A.C.R., Director, Office of Cosmetics and Colors, FDA.
Dr. Linda M. Katz is the Director of the Office of Cosmetics and Colors (OCAC) at the Center for Food Safety and Applied Nutrition (CFSAN), which regulates cosmetics and certifies colors used in foods, cosmetics, drugs, and devices. Dr. Katz joined FDA in 1989 in the Center for Drug Evaluation and Research (CDER) first as a primary medical officer and later as Team Leader and Acting Director of the Pilot Drug Evaluation Staff which reviewed anti-rheumatic drugs, anesthetic agents and drugs of abuse. Her subsequent appointments included: Deputy Director of the Division of Dermatologic and Dental Drug Products and Deputy Director of the Division of Over-the-Counter Drug Products. In 2002, Dr. Katz joined CFSAN in her present position and additionally served 10 years as the Acting Chief Medical Officer. Dr. Katz received her MD from the University of Connecticut School of Medicine, her MPH in Epidemiology from the University of Michigan School of Public Health, and her BA in Biology from the University of Pennsylvania. She did her internship and residency in Internal Medicine and fellowship in Rheumatology at the George Washington Medical Center. Dr. Katz is an elected Fellow in the American College of Physicians as well as a Fellow in the American College of Rheumatology. In addition, Dr. Katz has taught at Walter Reed Army Medical Center and the Uniformed Services University of the Health Sciences, and has numerous publications in the scientific and medical literature.

Dayle Lewis Cristinzio. Director, Stakeholder Engagement, Office of External Affairs, FDA. Ms. Cristinzio has more than 25 years of experience in public health policy development and advocacy as a Congressional staffer, representing health care clients in the private sector as a government affairs representative, and in various roles at the FDA. Ms. Cristinzio joined FDA in 2015 and served as the head of the Office of Legislation for two years where she managed the team through

passage of the 21st Century Cures legislation and the FDA's user fee reauthorizations act of 2017. She joined the Office of External Affairs at FDA in 2017 to lead the Stakeholder Engagement Staff and works closely with FDA Centers and Offices across the entire Agency. The Stakeholder Engagement Staff's mission is to build relationships with health professional organizations, patient groups, consumers, academia, and industry trade stakeholders, communicate timely agency policy announcements, and create strategic collaborations to better inform FDA's work.